BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild-type mice2

Journal of Neurochemistry

Volumn 99, Issue 6, 2006, Pages 1555-1563

  Nishitomi, Kouhei ^b   Sakaguchi, Gaku ^b   Horikoshi, Yuko ^c   Gray, Audrey J ^a   Maeda, Masahiro ^c   Hirata Fukae, Chiho ^a   Becker, Amanda G ^a   Hosono, Motoko ^b   Sakaguchi, Isako ^b   Minami, S Sakura ^a   Nakajima, Yoshihiro ^b   Li, Hui Fang ^a   Takeyama, Chie ^b   Kihara, Tsuyoshi ^b   Ota, Akinobu ^c   Wong, Philip C ^d   Aisen, Paul S ^a   Kato, Akira ^b   Kinoshita, Noriaki ^c   Matsuoka, Yasuji ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b SHIONOGI AND CO LTD   (Japan)

^c Immuno Biological Laboratories Co Ltd   (Japan)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Amyloid beta; Beta site amyloid precursor protein cleaving enzyme 1; Enzyme linked immunoabsorbance assay; Secretase; Soluble amyloid precursor protein alpha

Indexed keywords

ALPHA SECRETASE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE INHIBITOR;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE OVEREXPRESSION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; TRANSGENIC MOUSE; WILD TYPE;

AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ENDOPEPTIDASES; BLOTTING, WESTERN; CELLS, CULTURED; CEREBRAL CORTEX; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; GAMMA-AMINOBUTYRIC ACID; HUMANS; MICE; MICE, KNOCKOUT; NEURAL INHIBITION; NEURONS; TRIGLYCERIDES; UP-REGULATION;

MUS MUSCULUS;

EID: 33845515686     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2006.04178.x     Document Type: Article

References (33)

1. Aisen P. S. (2005) The development of anti-amyloid therapy for Alzheimer's disease: from secretase modulators to polymerisation inhibitors. CNS. Drugs 19, 989-996.
2. Anderson J. J., Holtz G., Baskin P. P. et al. (2005) Reductions in beta-amyloid concentrations in vivo by the gamma-secretase inhibitors BMS-289948 and BMS-299897. Biochem. Pharmacol.69, 689-698.
3. Barten D. M., Guss V. L., Corsa J. A. et al. (2005) Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of β-amyloid precursor protein transgenic mice treated with a gamma-secretase inhibitor. J. Pharmacol. Exp. Ther. 312, 635-643.
4. Cai H., Wang Y., McCarthy D., Wen H., Borchelt D. R., Price D. L. and Wong P. C. (2001) BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat. Neurosci. 4, 233-234.
5. Dovey H. F., John V., Anderson J. P. et al. (2001) Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J. Neurochem. 76, 173-181.
6. Fukumoto H., Tomita T., Matsunaga H., Ishibashi Y., Saido T. C. and Iwatsubo T. (1999) Primary cultures of neuronal and non-neuronal rat brain cells secrete similar proportions of amyloid beta peptides ending at A beta40 and A beta42. Neuroreport 10, 2965-2969.
7. Fukumoto H., Cheung B. S., Hyman B. T. and Irizarry M. C. (2002) Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch. Neurol. 59, 1381-1389.
8. Gouras G. K., Xu H., Jovanovic J. N., Buxbaum J. D., Wang R., Greengard P., Relkin N. R. and Gandy S. (1998) Generation and regulation of beta-amyloid peptide variants by neurons. J. Neurochem. 71, 1920-1925.
9. Haass C., Schlossmacher M. G., Hung A. Y., Vigo-Pelfrey C., Mellon A., Ostaszewski B. L., Lieberburg I., Koo E. H., Schenk D. and Teplow D. B. (1992) Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 359, 322-325.
10. Hardy J. and Selkoe D. J. (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356.
11. Holsinger R. M., McLean C. A., Beyreuther K., Masters C. L. and Evin G. (2002) Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease. Ann. Neurol. 51, 783-786.
12. Horikoshi Y., Sakaguchi G., Becker A. G., Gray A. J., Duff K., Aisen P. S., Yamaguchi H., Maeda M., Kinoshita N. and Matsuoka Y. (2004) Development of Abeta terminal end-specific antibodies and sensitive ELISA for Abeta variant. Biochem. Biophys. Res. Commun. 319, 733-737.
13. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F. and Cole G. (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274, 99-102.
14. Laird F. M., Cai H., Savonenko A. V. et al. (2005) BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J. Neurosci. 25, 11 693-11 709.
15. Lamb B. T., Sisodia S. S., Lawler A. M., Slunt H. H., Kitt C. A., Kearns W. G., Pearson P. L., Price D. L. and Gearhart J. D. (1993) Introduction and expression of the 400 kilobase amyloid precursor protein gene in transgenic mice. Nat. Genet. 5, 22-30.
16. Luo Y., Bolon B., Kahn S. et al. (2001) Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat. Neurosci. 4, 231-232.
17. Luo Y., Bolon B., Damore M. A., Fitzpatrick D., Liu H., Zhang J., Yan Q., Vassar R. and Citron M. (2003) BACE1 (beta-secretase) knockout mice do not acquire compensatory gene expression changes or develop neural lesions over time. Neurobiol. Dis. 14, 81-88.
18. Mattson M. P., Cheng B., Culwell A. R., Esch F. S., Lieberburg I. and Rydel R. E. (1993) Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the beta-amyloid precursor protein. Neuron 10, 243-254.
19. Mattson M. P., Barger S. W., Furukawa K., Bruce A. J., Wyss-Coray T., Mark R. J. and Mucke L. (1997) Cellular signaling roles of TGF beta, TNF alpha and beta APP in brain injury responses and Alzheimer's disease. Brain Res. Brain Res. Rev. 23, 47-61.
20. Mosmann T. (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Meth. 65, 55-63.
21. Rocca W. A., Hofman A., Brayne C. et al. (1991) Frequency and distribution of Alzheimer's disease in Europe: a collaborative study of 1980-90 prevalence findings. The EURODEM-Prevalence Research Group. Ann. Neurol. 30, 381-390.
22. Schubert D. and Behl C. (1993) The expression of amyloid beta protein precursor protects nerve cells from beta-amyloid and glutamate toxicity and alters their interaction with the extracellular matrix. Brain Res. 629, 275-282.
23. Singer O., Marr R. A., Rockenstein E., Crews L., Coufal N. G., Gage F. H., Verma I. M. and Masliah E. (2005) Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat. Neurosci. 8, 1343-1349.
24. Sinha S., Anderson J. P., Barbour R. et al. (1999) Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature 402, 537-540.
25. Skovronsky D. M., Moore D. B., Milla M. E., Doms R. W. and Lee V. M. (2000) Protein kinase C-dependent alpha-secretase competes with beta-secretase for cleavage of amyloid-beta precursor protein in the trans-golgi network. J. Biol. Chem. 275, 2568-2575.
26. Stachel S. J., Coburn C. A., Steele T. G. et al. (2004) Structure-based design of potent and selective cell-permeable inhibitors of human beta-secretase (BACE-1). J. Med. Chem. 47, 6447-6450.
27. Stachel S. J., Coburn C. A., Steele T. G., Crouthamel M. C., Pietrak B. L., Lai M. T., Holloway M. K., Munshi S. K., Graham S. L. and Vacca J. P. (2006) Conformationally biased P3 amide replacements of beta-secretase inhibitors. Bioorg. Med. Chem. Lett. 16, 641-644.
28. Suzuki N., Cheung T. T., Cai X. D., Odaka A., Otvos L., Jr, Eckman C., Golde T. E. and Younkin S. G. (1994) An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science 264, 1336-1340.
29. Tomasselli A. G., Qahwash I., Emmons T. L. et al. (2003) Employing a superior BACE1 cleavage sequence to probe cellular APP processing. J. Neurochem. 84, 1006-1017.
30. Vassar R., Bennett B. D., Babu-Khan S. et al. (1999) Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE [see comments]. Science 286, 735-741.
31. Willem M., Dewachter I., Van Smyth N. D. T., Borghgraef P., Haass C. and Van L. F. (2004) beta-site amyloid precursor protein cleaving enzyme 1 increases amyloid deposition in brain parenchyma but reduces cerebrovascular amyloid angiopathy in aging BACE x APP[V717I] double-transgenic mice. Am. J. Pathol. 165, 1621-1631.
32. Yan R., Bienkowski M. J., Shuck M. E. et al. (1999) Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature 402, 533-537.
33. Yang L. B., Lindholm K., Yan R. et al. (2003) Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat. Med. 9, 3-4.